Patents Assigned to CV Therapeutics
  • Sustained release ranolazine formulations
    Patent number: 6620814
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: September 16, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Fiona Baker, John Langridge
  • Sustained release ranolazine formulations
    Patent number: 6617328
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: September 9, 2003
    Assignees: CV Therapeutics, Inc, Syntex (USA), LLC
    Inventors: Andrew A. Wolff, Fiona Baker, John Langridge
  • Partial or full A1agonists-N-6 heterocyclic 5?-thio substituted adenosine derivatives
    Patent number: 6605597
    Abstract: N6 heterocyclic 5′ modified adenosine derivatives that are adenosine A1 receptor partial or full agonists, and as such, are useful for modifying cardiac activity, modifying adipocyte function, treating central nervous system disorders, and treating diabetic disorders and obesity in mammals, and especially in humans.
    Type: Grant
    Filed: December 3, 1999
    Date of Patent: August 12, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff A. Zablocki, Venkata P. Palle, Vaibhav Varkhedkar, Luiz Belardinelli
  • Method of preventing reperfusion injury
    Patent number: 6599283
    Abstract: Methods are disclosed for preventing or inhibiting reperfusion injury to the ischemic myocardium.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: July 29, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Mario Marzilli, Brent Blackburn
  • Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
    Publication number: 20030119718
    Abstract: Methods are disclosed for treating congestive heart failure with partial inhibitors of fatty acid oxidation. The compounds increase cardiac performance without affecting heart rate, blood pressure, or oxygen consumption.
    Type: Application
    Filed: August 27, 2002
    Publication date: June 26, 2003
    Applicant: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Brent Blackburn, Hani Naief Sabbah, William Clark Stanley
  • Method of identifying partial adenosine A1 receptor agonists
    Patent number: 6576620
    Abstract: The present invention provides a method for identifying partial adenosine A1 receptor agonists that are useful in the treatment of arrhythmias. Partial adenosine A1 receptor agonists and methods for using partial adenosine A1 receptor agonists to treat arrhythmias in mammals.
    Type: Grant
    Filed: December 1, 2000
    Date of Patent: June 10, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Luiz Belardinelli, Zhenhai Gao
  • Orally active A1 adenosine receptor agonists
    Patent number: 6576619
    Abstract: Esters of N6-oxa, thia, thioxa and azacycloalkyl substituted adenosine derivatives having the following formula; wherein the compounds are selective adenosine type 1 receptor agonists that are useful for the treatment cardiovascular diseases and central nervous system disorders.
    Type: Grant
    Filed: May 24, 1999
    Date of Patent: June 10, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Brent K. Blackburn, Chris Melville, Jeff A. Zablocki, Venkata P. Palle, Elfaith O. Elzein, Lisa Wang
  • Heteroaryl alkyl piperazine derivatives
    Patent number: 6573264
    Abstract: Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
    Type: Grant
    Filed: October 23, 2000
    Date of Patent: June 3, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff Zablocki, Prabha N. Ibrahim, Kevin Shenk, Elfatih Elzein, Venkata Palle
  • Sustained release ranolazine formulations
    Publication number: 20030100566
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Application
    Filed: September 27, 2002
    Publication date: May 29, 2003
    Applicant: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Fiona Baker, John Richard Langridge
  • Sustained release ranolazine formulations
    Publication number: 20030099705
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Application
    Filed: September 27, 2002
    Publication date: May 29, 2003
    Applicant: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Fiona Baker, John Richard Langridge
  • Sustained release ranolazine formulations
    Patent number: 6562826
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 850 and 4000 ng base/mL.
    Type: Grant
    Filed: September 25, 2002
    Date of Patent: May 13, 2003
    Assignee: CV Therapeutics, Inc.
    Inventor: Andrew A. Wolff
  • Aralkyl substituted piperazine compounds
    Patent number: 6552023
    Abstract: Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: April 22, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff Zablocki, Elfatih Elzein, Brent K. Blackburn, Tim Marquart, Prabha N. Ibrahim, Venkata P. Palle
  • ABCA-1 elevating compounds
    Patent number: 6548548
    Abstract: The present invention provides compounds that elevate cellular expression of the ABCA-1 gene, promoting cholesterol efflux from cells and increasing HDL levels in the plasma of a mammal, in particular humans. The compounds are useful for treating coronary artery disease.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: April 15, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Michael Campbell, Prabha N. Ibrahim, Jeff A. Zablocki, Richard Lawn
  • Substituted alkyl piperazine derivatives
    Publication number: 20030064994
    Abstract: Novel compounds of the general formula: 1
    Type: Application
    Filed: September 13, 2002
    Publication date: April 3, 2003
    Applicant: CV Therapeutics, Inc.
    Inventors: Vaibhav Varkhedkar, Venkata P. Palle, Jeff Zablocki, Elfatih Elzein, Brent K. Blackburn
  • Method of treating arrhythmias
    Patent number: 6537974
    Abstract: A method for treating arrhythmia in mammals is provided comprising administering a low dose of an adenosine receptor agonist of the Formula I: wherein R1 is an optionally substituted heterocyclic group, preferably monocyclic.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: March 25, 2003
    Assignee: CV Therapeutics, Inc.
    Inventor: Andrew Wolff
  • Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
    Patent number: 6528511
    Abstract: Methods are disclosed for treating congestive heart failure with partial inhibitors of fatty acid oxidation. The compounds increase cardiac performance without affecting heart rate, blood pressure, or oxygen consumption.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: March 4, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Brent Blackburn, Hani Naief Sabbah, William Clark Stanley
  • Sustained release ranolazine formulations
    Patent number: 6525057
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Grant
    Filed: August 9, 2001
    Date of Patent: February 25, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Fiona Baker, John Langridge
  • Sustained release ranolazine formulations
    Patent number: 6503911
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: January 7, 2003
    Assignees: CV Therapeutics, Inc., Syntex USA, Inc.
    Inventors: Andrew A. Wolff, Fiona Baker, John Langridge
  • Methods for treating angina with ranolazine
    Patent number: 6479496
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 850 and 4000 ng base/mL.
    Type: Grant
    Filed: March 8, 2000
    Date of Patent: November 12, 2002
    Assignee: CV Therapeutics, Inc.
    Inventor: Andrew A. Wolff
  • Substituted alkyl piperazine derivatives
    Patent number: 6451798
    Abstract: Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: September 17, 2002
    Assignee: CV Therapeutics, Inc.
    Inventors: Vaibhav Varkhedkar, Venkata P. Palle, Jeff Zablocki, Elfatih Elzein, Brent K. Blackburn